Clinical Utility Study for Exo-PDAC

Status Withdrawn

Clinical Trial Summary

This is a national-level research study of oncologists, interventional gastroenterologists, and primary care providers. The purpose of this study is to assess the clinical evaluation and management (drug, procedures, counseling and other) of a subset of common patient care indications.

Clinical Trial Description

The results of this study could contribute to improved quality of care for patients by encouraging better care practices and adherence to evidence-based guidance. The data from this study will be submitted to a national journal for publication. The study plans to enroll up to 250 physicians. Upon consenting and agreeing to participate in this study, participants will be asked to care for 3 simulated patient cases, known as Clinical Performance and Value Vignettes (CPV®). CPV®s describe patients physicians typically encounter in their daily practice and are not meant to be difficult. In each vignette, physicians are asked to share their expected care through 5 domains: 1) history, 2) physical exam, 3) diagnostic workup, 4) diagnosis and 5) treatment and follow-up. Each case takes approximately 15-20 minutes to complete and we estimate the time commitment for each round of CPV® administration to be approximately 45 - 60 minutes. All responses to the cases will be completed online and will be kept confidential. Over 2 CPV® administration rounds, the total time to care for the simulated patients is estimated at 1.5-2 hours. If physicians are randomized to an intervention group in this study, they will receive educational materials on a novel diagnostic test after the first round of CPV® administration. They are asked to review these materials before moving to the next CPV® administration round. The time to review educational materials is estimated to be approximately 15 minutes. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05702385
Study type	Interventional
Source	Qure Healthcare, LLC
Contact
Status	Withdrawn
Phase	N/A
Start date	September 1, 2023
Completion date	October 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT05435053` - Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer	Phase 2
Recruiting	`NCT06006390` - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors	Phase 1/Phase 2
Completed	`NCT03109041` - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source	Phase 1
Recruiting	`NCT06065891` - Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer	N/A
Recruiting	`NCT06010862` - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors	Phase 1
Recruiting	`NCT05048524` - Peri-operative SLOG for Localized Pancreatic Cancer	Phase 2
Suspended	`NCT05124743` - HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Recruiting	`NCT05351983` - Patient-derived Organoids Drug Screen in Pancreatic Cancer	N/A
Recruiting	`NCT05679674` - Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer	N/A
Recruiting	`NCT05501379` - Comparison of the Physical Activity in Cancer Patients Assessed by Questionnaire and Motion Tracker
Recruiting	`NCT04851106` - Evaluation of Endoscopic Ultrasound Shear Wave Elastography (EUS-SWE) for the Diagnosis of Pancreatic Adenocarcinoma.
Enrolling by invitation	`NCT04466189` - Prospective Cohort Study of Pancreatic Cancer Patients Treated With Proton Beam Therapy
Not yet recruiting	`NCT06036563` - Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing
Terminated	`NCT01313416` - Gemcitabine and CT-011 for Resected Pancreatic Cancer	Phase 2
Recruiting	`NCT01411072` - Biomarker Directed Adjuvant Chemotherapy for Resected Pancreas Cancer	N/A
Active, not recruiting	`NCT01448668` - Iscador Qu as Supportive Treatment in Pancreatic Cancer (Union for International Cancer Control, UICC Stages II-IV)	N/A
Completed	`NCT01155882` - Registry Study - Whipple at the Splenic Artery
Recruiting	`NCT04970056` - Pancreatic Cancer Early Detection Consortium
Recruiting	`NCT04140526` - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC	Phase 1/Phase 2
Withdrawn	`NCT03682744` - CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)	Phase 1